Nov. 12 at 3:04 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics (
$CVKD) – 3Q25 Reported With Product Pipeline Updates
Cadrenal Made A Significant Acquisition In 3Q25. Cadrenal reported a loss of
$2.7 million or $(1.31) per share, less than the loss of
$3.1 million we estimated. The company also provided an update on clinical progress for tecarfarin and the products acquired through the recent acquisition of eXithera Therapeutics. At the end of the quarter on September 30, the company had cash on hand of
$3.9 million.
Read more: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-3q25-reported-with-product-pipeline-updates
